Mostrar el registro sencillo del ítem

dc.contributor.author
Cardinali, Daniel Pedro  
dc.contributor.author
Hardeland, Rüdiger  
dc.date.available
2018-06-07T18:24:35Z  
dc.date.issued
2017-04  
dc.identifier.citation
Cardinali, Daniel Pedro; Hardeland, Rüdiger; Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies; Karger; Neuroendocrinology; 104; 4; 4-2017; 382-397  
dc.identifier.issn
0028-3835  
dc.identifier.uri
http://hdl.handle.net/11336/47714  
dc.description.abstract
The metabolic syndrome (MS) is a collection of risk factors for cardiovascular disease, including obesity, hypertension, hyperinsulinemia, glucose intolerance and dyslipidemia. MS is associated with low-grade inflammation of the white adipose tissue, which can subsequently lead to insulin resistance, impaired glucose tolerance and diabetes. Adipocytes secrete proinflammatory cytokines as well as leptin and trigger a vicious circle which leads to additional weight gain largely as fat. The imbalance between inflammatory and anti-inflammatory signals is crucial to aging. Healthy aging can benefit from melatonin, a compound known to possess direct and indirect antioxidant properties, to have a significant protective effect on mitochondrial function, to enhance circadian rhythm amplitudes, to modulate the immune system and to exhibit neuroprotective actions. Melatonin levels decrease in the course of senescence and are more strongly reduced in diseases related to insulin resistance. This short review article analyzes the multiple protective actions of melatonin that are relevant to the attenuation of inflammatory responses and progression of inflammaging and how melatonin is effective to curtail MS in animal models of hyperadiposity. The clinical data supporting the possible therapeutic use of melatonin in human MS are also reviewed. Since attention has been focused on the development of potent melatonin analogs with prolonged effects (ramelteon, agomelatine, tasimelteon, piromelatine) and in clinical trials these analogs were administered in doses considerably higher than those usually employed for melatonin, clinical trials on melatonin in the range of 50-100 mg/day are needed to further assess its therapeutic value in MS.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Karger  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Melatonin  
dc.subject
Metabolic Syndrome  
dc.subject
Inflammation  
dc.subject
Diabetes  
dc.subject
Obesity  
dc.subject
Insulin Signaling  
dc.subject
Aging  
dc.subject.classification
Inmunología  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2018-06-07T14:25:58Z  
dc.identifier.eissn
1423-0194  
dc.journal.volume
104  
dc.journal.number
4  
dc.journal.pagination
382-397  
dc.journal.pais
Suiza  
dc.journal.ciudad
Basilea  
dc.description.fil
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina ; Argentina  
dc.description.fil
Fil: Hardeland, Rüdiger. Universität Göttingen; Alemania  
dc.journal.title
Neuroendocrinology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1159/000446543  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.karger.com/Article/Abstract/446543